Stay updated on Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedAdded: Revision: v3.4.2. Removed: the funding-status notice and Revision: v3.4.1 banner. These changes do not affect the study details or the information presented on the page.SummaryDifference0.4%

- Check21 days agoChange DetectedNew site-wide notice about government funding and NIH operating status is displayed at the top of the page. The page header now shows a Revision: v3.4.1, replacing the previous Revision: v3.4.0.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a 'Show glossary' option. Updated metadata to display 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', while removing the older 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' entries.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed. This appears to be a behind-the-scenes update with no impact on study content or user-facing information.SummaryDifference0.0%

- Check63 days agoChange DetectedThe Locations section was updated to add new study sites across the US, France, Japan, Russia, Spain, and the UK, and the revision version was updated to v3.3.3.SummaryDifference2%

- Check85 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 is shown on the page. This is a minor internal update that does not affect study content or user-facing information, and To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Hepatocellular Carcinoma Clinical Trial page.